Neuronetics Q1 2026 Earnings Call Insights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 05 2026
0mins
Source: seekingalpha
- Performance in Line: Neuronetics reported total revenue of $34.5 million in Q1, with NeuroStar contributing $12.9 million; however, TMS volumes were slightly below last year due to weather disruptions, indicating market volatility.
- Cost Structure Optimization: The company implemented measures to realign its cost structure, expected to yield annual savings of approximately $2.5 million to $3 million, with net savings beginning in Q3, aiming to enhance profitability and cash flow to ensure financial health.
- Leadership Transition: New CEO Daniel Reuvers noted the departure of former CFO Steve Fansteel earlier this month, with an active search for his successor underway, which may impact the stability of strategic execution.
- Stable Future Outlook: Management maintained its 2026 total revenue guidance between $160 million and $166 million; despite cash flow pressures, operating cash flow is projected to improve sequentially in Q2, reflecting confidence in future growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy STIM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on STIM
Wall Street analysts forecast STIM stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.540
Low
7.00
Averages
7.00
High
7.00
Current: 1.540
Low
7.00
Averages
7.00
High
7.00
About STIM
Neuronetics, Inc. a vertically integrated, commercial stage, medical technology and healthcare company. The Company’s NeuroStar Advanced Therapy (NeuroStar Therapy) is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions. In addition to selling the NeuroStar Advanced Therapy System (NeuroStar System) and associated treatment sessions to customers, it operates Greenbrook treatment centers across the United States, offering NeuroStar Therapy for the treatment of major depressive disorder (MDD) and other mental health disorders. Spravato is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. MDD is a recurrent disease and follows a fluctuating course over an individual’s lifetime. The Company provides more than 7.1 million treatments to over 1,95,000 patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Neuronetics Partners with ANT Neuro to Enhance NeuroStar Therapy
- Strategic Partnership: Neuronetics has formed a partnership with ANT Neuro to integrate the visor2™ neuronavigation system with NeuroStar TMS, aiming to enhance treatment visualization and personalization, which is expected to significantly improve patient treatment experiences and outcomes.
- Technological Integration: By incorporating ANT Neuro's FDA-cleared technology, the NeuroStar system will enable real-time spatial tracking and 3D visualization, enhancing consistency and confidence throughout the treatment process, thereby improving the quality of healthcare services.
- Market Leadership: With the largest installed base of TMS systems in the U.S., this collaboration will further solidify Neuronetics' leadership position in the rapidly evolving TMS market, addressing healthcare providers' increasing demand for advanced technologies.
- Industry Showcase Plans: The partnership will be showcased at the upcoming American Psychiatric Association Annual Meeting and the Clinical TMS Society Annual Meeting, with broader rollout plans set for the second half of 2026, aiming to expand market influence further.
See More
Neuronetics Q1 2026 Earnings Call Insights
- Performance in Line: Neuronetics reported total revenue of $34.5 million in Q1, with NeuroStar contributing $12.9 million; however, TMS volumes were slightly below last year due to weather disruptions, indicating market volatility.
- Cost Structure Optimization: The company implemented measures to realign its cost structure, expected to yield annual savings of approximately $2.5 million to $3 million, with net savings beginning in Q3, aiming to enhance profitability and cash flow to ensure financial health.
- Leadership Transition: New CEO Daniel Reuvers noted the departure of former CFO Steve Fansteel earlier this month, with an active search for his successor underway, which may impact the stability of strategic execution.
- Stable Future Outlook: Management maintained its 2026 total revenue guidance between $160 million and $166 million; despite cash flow pressures, operating cash flow is projected to improve sequentially in Q2, reflecting confidence in future growth.
See More
Neuronetics Q1 Earnings Report Analysis
- Earnings Performance: Neuronetics reported a Q1 GAAP EPS of -$0.16, indicating a loss, yet revenue reached $34.5 million, reflecting a 9.9% year-over-year growth, showcasing the company's potential for growth even in adversity.
- Revenue Growth: The revenue increase, despite challenges, suggests strong market demand for Neuronetics' products, potentially laying the groundwork for a future stock rebound.
- Executive Change: CFO Steven Pfanstiel is set to depart, with the company initiating a search for a successor, which may impact investor confidence in the company's future financial management.
- Market Evaluation: While Neuronetics is considered a highly speculative stock, its revenue growth could attract investor interest, particularly amid overall market underperformance.
See More
Neuronetics Projects FY Revenue Between USD 160 Million and USD 166 Million
Company Overview: NeuroNetics is focused on developing innovative solutions in the field of neuroscience and mental health.
Financial Performance: The company reported a revenue range of $160 million to $166 million for the fiscal year.
See More
Neuronetics Grants Inducement Awards to Six New Employees
- Inducement Awards Granted: Neuronetics has awarded inducement awards totaling 118,000 restricted stock units to six new non-executive employees, aimed at attracting and retaining talent, thereby enhancing the company's competitive edge in the neurohealth sector.
- Award Details: The stock units vest based on each employee's continued service, ensuring they contribute value to the company over the next three to four years, reflecting the company's commitment to talent and long-term strategic development.
- Market Positioning: As a global leader in neuroscience, Neuronetics is dedicated to providing non-drug, non-invasive treatment options, having delivered over 7.4 million NeuroStar Advanced Therapy treatments, further solidifying its leadership in the depression treatment market.
- Treatment Center Expansion: The company operates Greenbrook TMS Inc. treatment centers across the U.S., offering NeuroStar Advanced Therapy to meet the needs of treatment-resistant depression patients, demonstrating its ongoing investment and market expansion potential in mental health.
See More
Neuronetics Expands Access to TMS Therapy
- Policy Update: Optum/UHC/UBH has revised its Transcranial Magnetic Stimulation (TMS) clinical policy to allow psychiatric mental health nurse practitioners (PMHNPs) to order, supervise, and administer TMS therapy, previously restricted to psychiatrists, significantly enhancing access to TMS treatment.
- Expanded Coverage: The new policy applies to PMHNPs in 26 states and Washington, D.C., where full practice authority is granted, thereby increasing access to NeuroStar TMS therapy for 34.8 million Optum/UHC/UBH commercial covered lives, addressing the growing demand for mental health services.
- Patient Benefits: According to the NeuroStar Outcomes Database, patients receiving NeuroStar treatment achieved an 83% response rate and a 62% remission rate for major depressive disorder (MDD), indicating the treatment's significant effectiveness in improving patient quality of life.
- Industry Leadership: Neuronetics stands out as the only TMS company with a dedicated health policy team that collaborates with providers and payors to advocate for health policy updates, further solidifying its leadership position in the neurohealth sector.
See More
Neuronetics Partners with ANT Neuro to Enhance NeuroStar Therapy
- Strategic Partnership: Neuronetics has formed a partnership with ANT Neuro to integrate the visor2™ neuronavigation system with NeuroStar TMS, aiming to enhance treatment visualization and personalization, which is expected to significantly improve patient treatment experiences and outcomes.
- Technological Integration: By incorporating ANT Neuro's FDA-cleared technology, the NeuroStar system will enable real-time spatial tracking and 3D visualization, enhancing consistency and confidence throughout the treatment process, thereby improving the quality of healthcare services.
- Market Leadership: With the largest installed base of TMS systems in the U.S., this collaboration will further solidify Neuronetics' leadership position in the rapidly evolving TMS market, addressing healthcare providers' increasing demand for advanced technologies.
- Industry Showcase Plans: The partnership will be showcased at the upcoming American Psychiatric Association Annual Meeting and the Clinical TMS Society Annual Meeting, with broader rollout plans set for the second half of 2026, aiming to expand market influence further.
See More
Neuronetics Q1 2026 Earnings Call Insights
- Performance in Line: Neuronetics reported total revenue of $34.5 million in Q1, with NeuroStar contributing $12.9 million; however, TMS volumes were slightly below last year due to weather disruptions, indicating market volatility.
- Cost Structure Optimization: The company implemented measures to realign its cost structure, expected to yield annual savings of approximately $2.5 million to $3 million, with net savings beginning in Q3, aiming to enhance profitability and cash flow to ensure financial health.
- Leadership Transition: New CEO Daniel Reuvers noted the departure of former CFO Steve Fansteel earlier this month, with an active search for his successor underway, which may impact the stability of strategic execution.
- Stable Future Outlook: Management maintained its 2026 total revenue guidance between $160 million and $166 million; despite cash flow pressures, operating cash flow is projected to improve sequentially in Q2, reflecting confidence in future growth.
See More
Neuronetics Q1 Earnings Report Analysis
- Earnings Performance: Neuronetics reported a Q1 GAAP EPS of -$0.16, indicating a loss, yet revenue reached $34.5 million, reflecting a 9.9% year-over-year growth, showcasing the company's potential for growth even in adversity.
- Revenue Growth: The revenue increase, despite challenges, suggests strong market demand for Neuronetics' products, potentially laying the groundwork for a future stock rebound.
- Executive Change: CFO Steven Pfanstiel is set to depart, with the company initiating a search for a successor, which may impact investor confidence in the company's future financial management.
- Market Evaluation: While Neuronetics is considered a highly speculative stock, its revenue growth could attract investor interest, particularly amid overall market underperformance.
See More
Neuronetics Projects FY Revenue Between USD 160 Million and USD 166 Million
Company Overview: NeuroNetics is focused on developing innovative solutions in the field of neuroscience and mental health.
Financial Performance: The company reported a revenue range of $160 million to $166 million for the fiscal year.
See More
Neuronetics Grants Inducement Awards to Six New Employees
- Inducement Awards Granted: Neuronetics has awarded inducement awards totaling 118,000 restricted stock units to six new non-executive employees, aimed at attracting and retaining talent, thereby enhancing the company's competitive edge in the neurohealth sector.
- Award Details: The stock units vest based on each employee's continued service, ensuring they contribute value to the company over the next three to four years, reflecting the company's commitment to talent and long-term strategic development.
- Market Positioning: As a global leader in neuroscience, Neuronetics is dedicated to providing non-drug, non-invasive treatment options, having delivered over 7.4 million NeuroStar Advanced Therapy treatments, further solidifying its leadership in the depression treatment market.
- Treatment Center Expansion: The company operates Greenbrook TMS Inc. treatment centers across the U.S., offering NeuroStar Advanced Therapy to meet the needs of treatment-resistant depression patients, demonstrating its ongoing investment and market expansion potential in mental health.
See More
Neuronetics Expands Access to TMS Therapy
- Policy Update: Optum/UHC/UBH has revised its Transcranial Magnetic Stimulation (TMS) clinical policy to allow psychiatric mental health nurse practitioners (PMHNPs) to order, supervise, and administer TMS therapy, previously restricted to psychiatrists, significantly enhancing access to TMS treatment.
- Expanded Coverage: The new policy applies to PMHNPs in 26 states and Washington, D.C., where full practice authority is granted, thereby increasing access to NeuroStar TMS therapy for 34.8 million Optum/UHC/UBH commercial covered lives, addressing the growing demand for mental health services.
- Patient Benefits: According to the NeuroStar Outcomes Database, patients receiving NeuroStar treatment achieved an 83% response rate and a 62% remission rate for major depressive disorder (MDD), indicating the treatment's significant effectiveness in improving patient quality of life.
- Industry Leadership: Neuronetics stands out as the only TMS company with a dedicated health policy team that collaborates with providers and payors to advocate for health policy updates, further solidifying its leadership position in the neurohealth sector.
See More
